Webinar Overview

In this brief webinar, Dr. William Reed, Director of Clinical Research and Medical Affairs at Cerus Corporation, outlines several of the key INTERCEPT presentations from the 12th International Hemovigilance Seminar (IHS), held in Dubrovnik, Croatia, February 17 -19, 2010. The IHS meeting was an opportunity for hematologists and epidemiologists to review current global and regional trends in transfusion safety. Investigators from multiple independent blood centers in Sweden, Belgium, France and Slovenia shared extensive multi-year safety data with routine use of the INTERCEPT Blood System for platelets and plasma. Citing decreased adverse transfusion reactions compared to conventional platelet components, the observations from these active hemovigilance efforts serve to confirm and extend the safety profile for INTERCEPT. Dr. Reed covers the highlights of these presentations including the following:

3-year EFS Alsace platelet experience: n=42,465

6-year Mont-Godinne experience: evaluation of central nervous system bleeding before and after the introduction of INTERCEPT

Multi-site European HV experience: n=18,641

INTERCEPT is beginning to introduce a new paradigm in transfusion medicine – beyond pathogen inactivation:

Speaker Bio

William F. Reed, M.D. received his medical degree from Brown University. He completed fellowships in Pediatric Hematology/Oncology at Children’s Hospital and Research Institute in Oakland and in Transfusion Medicine at Blood Centers of the Pacific in San Francisco. Prior to joining Cerus in late 2009, he was an Investigator for ten years at Blood Systems Research Institute in San Francisco. Dr. Reed has been a faculty member at the University of California San Francisco School of Medicine where he was the first Medical Director and helped to establish the University’s Human Islet and Cellular Transplantation Laboratory. Dr. Reed has also served as Medical Director for the Northern California Region of the American Red Cross. His research interests include hemoglobinopathies, placental blood banking & transplantation and leukocyte microchimerism following transfusion. At Cerus, he is also taking a special interest in the causes and treatment of anemia in the developing world.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.